Literature DB >> 19778298

Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan.

Y-C Hsieh1, L-Y Chang, Y-C Huang, H-C Lin, L-M Huang, P-R Hsueh.   

Abstract

Levofloxacin susceptibility testing was carried out for a total of 2539 Streptococcus pneumoniae isolates obtained from January 2001 to February 2008 at the National Taiwan University Hospital (NTUH) and a further 228 pneumococcal isolates obtained from January 2004 to December 2006 at three other hospitals in different geographical areas in Taiwan. Levofloxacin non-susceptible S. pneumoniae isolates were subsequently analysed for serotype and molecular epidemiology. Rates of levofloxacin non-susceptibility of S. pneumoniae increased significantly from 1.2% in 2001 to 4.2% in 2007 at NTUH. A total of 30 isolates of levofloxacin non-susceptible S. pneumoniae isolates (MIC ≥ 4 mg/L) were available for evaluation of serotype, antimicrobial susceptibility, nucleotide sequence of the quinolone resistance-determining regions of parC, gyrA, parE and gyrB, reserpine effect on quinolone susceptibility and multilocus sequence type. Among these isolates, seven (23.3%) were from children, and two (6.7%; one from a 3- and one from a 93-year-old patient) were from blood. One levofloxacin-resistant isolate (MIC = 8 mg/L) was recovered from a previously healthy child with bacteraemic necrotizing pneumonia complicated by empyema and a haemolytic-uraemic syndrome. All isolates except two had Ser79 and/or Asp83 changes in ParC, and/or Ser81 or Glu85 changes in GyrA. An efflux phenotype concerning levofloxacin was detected in only one (3.3%) isolate. A novel clone (ST3642), genetically related to Spain(9V)-3 and belonging to serotype 11A, was identified. Dissemination of clonal complexes related to Spain(23F)-1, Taiwan(19F)-14, Spain(9V)-3 and Taiwan(23F)-15 has contributed to levofloxacin non-susceptibility among these S. pneumoniae isolates from Taiwan.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19778298     DOI: 10.1111/j.1469-0691.2009.02951.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Bacteremic pneumonia caused by extensively drug-resistant Streptococcus pneumoniae.

Authors:  Cheol-In Kang; Jin Yang Baek; Kyeongman Jeon; So Hyun Kim; Doo Ryeon Chung; Kyong Ran Peck; Nam Yong Lee; Jae-Hoon Song
Journal:  J Clin Microbiol       Date:  2012-10-10       Impact factor: 5.948

2.  Novel Levofloxacin-Resistant Multidrug-Resistant Streptococcus pneumoniae Serotype 11A Isolates, South Korea.

Authors:  Miey Park; Hyun Soo Kim; Han-Sung Kim; Ji Young Park; Wonkeun Song; Hyoun Chan Cho; Jae-Seok Kim
Journal:  Emerg Infect Dis       Date:  2016-11       Impact factor: 6.883

Review 3.  Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.

Authors:  Miklos Fuzi; Dora Szabo; Rita Csercsik
Journal:  Front Microbiol       Date:  2017-11-16       Impact factor: 5.640

Review 4.  Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.

Authors:  Gwan-Han Shen; Thomas Chang-Yao Tsao; Shang-Jyh Kao; Jen-Jyh Lee; Yen-Hsu Chen; Wei-Chung Hsieh; Gwo-Jong Hsu; Yen-Tao Hsu; Ching-Tai Huang; Yeu-Jun Lau; Shih-Ming Tsao; Po-Ren Hsueh
Journal:  Int J Antimicrob Agents       Date:  2012-01-28       Impact factor: 5.283

Review 5.  Antimicrobial resistance in Asia: current epidemiology and clinical implications.

Authors:  Cheol-In Kang; Jae-Hoon Song
Journal:  Infect Chemother       Date:  2013-03-29

Review 6.  Community-Acquired Pneumonia in the Asia-Pacific Region.

Authors:  Jae-Hoon Song; Kyungmin Huh; Doo Ryeon Chung
Journal:  Semin Respir Crit Care Med       Date:  2016-12-13       Impact factor: 3.119

7.  Global Evolution of Pathogenic Bacteria With Extensive Use of Fluoroquinolone Agents.

Authors:  Miklos Fuzi; Jesus Rodriguez Baño; Akos Toth
Journal:  Front Microbiol       Date:  2020-02-25       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.